Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

NCT07101159 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

200

Enrollment

OTHER_GOV

Sponsor class

Conditions

Early Breast Cancer
Adjuvant Therapy
Hormone Receptor Positive / HER2-negative Breast Cancer

Interventions

DRUG: Dalpiciclib
DRUG: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
DRUG: Dalpiciclib

Sponsor

Fujian Cancer Hospital